Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice

Autor: Church, Rachel J., Gatti, Daniel M., Urban, Thomas J., Long, Nanye, Yang, Xi, Shi, Qiang, Eaddy, J. Scott, Mosedale, Merrie, Ballard, Shawn, Churchill, Gary A., Navarro, Victor, Watkins, Paul B., Threadgill, David W., Harrill, Alison H. ^*

Publikováno v: In Food and Chemical Toxicology February 2015 76:19-26

Editor’s Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach

Autor: Mosedale, Merrie, Kim, Yunjung, Brock, William J., Roth, Sharin E., Wiltshire, Tim, Eaddy, J. Scott, Keele, Gregory R., Corty, Robert W., Xie, Yuying, Valdar, William, Watkins, Paul B.

Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population. To

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cccf287aac15a32472d2176e9c9b8b93
https://europepmc.org/articles/PMC6075566/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.

Autor: Mosedale M; Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Research Triangle Park, North Carolina 27709.; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599., Kim Y; Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Research Triangle Park, North Carolina 27709.; Department of Genetics, UNC School of Medicine, Chapel Hill, North Carolina 27599., Brock WJ; Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville, Maryland 20850.; Brock Scientific Consulting, Montgomery Village, Maryland 20886., Roth SE; Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville, Maryland 20850., Wiltshire T; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599.; Department of Genetics, UNC School of Medicine, Chapel Hill, North Carolina 27599., Eaddy JS; Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Research Triangle Park, North Carolina 27709.; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599., Keele GR; Department of Genetics, UNC School of Medicine, Chapel Hill, North Carolina 27599., Corty RW; Department of Genetics, UNC School of Medicine, Chapel Hill, North Carolina 27599., Xie Y; Department of Genetics, UNC School of Medicine, Chapel Hill, North Carolina 27599., Valdar W; Department of Genetics, UNC School of Medicine, Chapel Hill, North Carolina 27599.; Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599., Watkins PB; Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Research Triangle Park, North Carolina 27709.; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599.

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2017 Apr 01; Vol. 156 (2), pp. 438-454.